Asset profile
morf-057
Small molecule
Evidence outlook · no controlled comparison
EMERALD-1 (NCT05291689) · Inflammatory Bowel Diseases, Colitis, Ulcerative
The lead study is single-arm or otherwise uncontrolled, so it produced no formal comparison against a control. This tier describes the design, not an outcome.
EMERALD-1 (NCT05291689): This was a single-group, open-label study with 39 participants overall and no placebo or active comparator. The primary clinical/histopathology endpoint was reported as a mean change, but without a comparator there was no formal between-group comparison to establish efficacy.
Also in development:Ulcerative Colitis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
86 competitors in this universe: 2 direct rivals (same mechanism and indication), 1 same-class, 83 same-indication; 69 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Morf-057: this drug | Phase 2 | Small molecule | α4β7 integrin | ||
| Vedolizumab (Entyvio) | Approved | Monoclonal antibody | α4β7 integrin | ||
| SPY001 | Phase 2 | Monoclonal antibody | α4β7 integrin | ||
| Trosunilimab | Phase 2 | Monoclonal antibody | α4β7 integrin | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Aacf (Idacio) | Approved | — | TNF-alpha | ||
| Adalimumab-Aaty (Yuflyma) | Approved | — | TNF-alpha | ||
| Adalimumab-Adaz (Hyrimoz) | Approved | — | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Afzb (Abrilada) | Approved | — | TNF-alpha | ||
| Adalimumab-Aqvh (Yusimry) | Approved | — | TNF-alpha | ||
| Adalimumab-Atto (Amjevita) | Approved | — | TNF-alpha | ||
| Adalimumab-Bwwd (Hadlima) | Approved | — | TNF-alpha | ||
| Adalimumab-Fkjp (Hulio) | Approved | — | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Balsalazide Disodium (Colazal) | Approved | — | Aminosalicylate |
…and 71 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (1)
May 2027 (1)
What to watch
2028 (1)
September 2028 (1)
What to watch
2030 (1)
June 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.